COVID-19: REPLICATION INHIBITORS AS PROMISING THERAPY FOR SYMPTOMATIC PATIENTS

Haghamad Allzain 1, Yassir Hamadalnil 2

1 Assistant Professor in the Department of Biochemistry, Faculty of Medicine, Shendi University, Sudan.
2 Department of Clinical Microbiology, Faculty of Medicine, Nile University, Khartoum, Sudan.

ABSTRACT

COVID-19 is unprecedented pandemic threading the mankind existence in the recent time, with globally reported (256,966,237) confirmed cases, including (5,151,643) death, as of 22 of November 2021 WHO (2020). The COVID-19 vaccine doses administered globally were (7,408,870,760) doses as of 22 of November 2021 WHO (2020). Strategy to face this serious threat include prevention of getting infection and rational treatment of symptomatic infected ones. Treatment can adopt one or all of the three strategies; prohibiting the virus from entry into the human cells, halt replication of the virus inside the human cells, and neutralizing the inflammatory and other effects of the virus pathogenicity.

Replication inhibitors are important tool in the tools box against COVID-19, however they are not substitute for vaccination against COVID-19 and other adopted preventive measurements. Still prevention is the best medicine for any disease. The aim of this review is to further explore the replication inhibitors as emerging tools for treatment of symptomatic cases of COVID-19. Many encouraging results have emerged from recent clinical trials. This may help to bridge the gap in existence knowledge and stimulate further discussion to enhance conducting more clinical trials for the treatment of COVID-19 and repurpose already existing other viral replicating indictors for treatment of COVID-19. Remdesivir, Molnupiravir and Paxlovid are promising viral replicating inhibitors drugs for treatment of symptomatic COVID-19 patients. Since Molnupiravir and Paxlovid are given orally as five days short course, are significantly of great value for low-income countries.

Keywords: COVID-19, Coronavirus, Remdesivir, Molnupiravir, Paxlovid

1. INTRODUCTION

Coronaviruses belong to the Coronaviridae family in the order Nidovirales, it possesses a crown-like spikes on the outer surface of the virus; so, it was named Boopathi et al. (2020), Coronaviruses size is (65–125 nm) in diameter and contain a positive sense, single-stranded RNA as a nucleic material with size ranging from 26 to 32kbs in length Schoeman and Fielding (2019). The subgroups of coronaviruses family are alpha (α), beta (β), gamma (γ) and delta (δ) coronavirus. Beta. These viruses were thought to infect only animals until the world witnessed a severe acute respiratory syndrome (SARS) outbreak caused by SARS-CoV, 2002 in Guangdong, China. Another pathogenic coronavirus, known as Middle East respiratory syndrome coronavirus (MERS-CoV) caused an endemic in Middle Eastern Countries. a decade later Harapan and Itoh. (2020)
Khan et al. (2020). However, beta-coronaviruses are clinically important group because they comprise the most highly pathogenic viruses against humans, including SARS-CoV-2, MERS-CoV, and SARS-CoV Khan et al. (2020), Cui et al. (2019).

2. CORONA VIRUS STRUCTURE

The characteristic morphology of Corona virus is spherical envelope, with club-shaped projections, that look like solar corona or a crown and made of a highly glycosylated protein called spike protein. It has other three structural proteins, envelope, membrane, and nucleocapsid. The virus genome is single strand positive-sense RNA, that is similar to host mRNA of approximately (26 to 32) kb. The first two-thirds of the genome consists of two large overlapping open reading frames that encode sixteen (16) nonstructural proteins, including proteases, RNA-dependent RNA polymerase (prRdRp), RNA helicase, primase, and others, that form the viral replicase complex, a platform to propagate viral mRNAs. The remaining portion of the genome includes interspersed open reading frames for the structural proteins, as well as a number of accessory proteins generally nonessential for replication in tissue culture but capable of suppressing immune responses and enhancing pathogenesis. The nonstructural proteins are all potential targets for therapies, which would in theory work against all corona viruses. Bergmann and Silverman (2020).

Symptoms of COVID-19 starts from two days to two weeks after exposure to the virus with mean incubation period of about five (5) days WHO (2020). Presentations of COVID-19 have ranged from asymptomatic, mild symptoms, to severe illness and death. Common symptoms have included fever, cough, and shortness of breath. Other symptoms, such as malaise and respiratory distress, have also been described Lauer et al. (2020), Hui et al. (2020).

Viral genome replication is essential step in the virus life cycle and it is a potential site for antiviral intervention, such as chain terminators and other antiviral drugs acting by inhibiting different steps in the virus life cycle.

The development of effective intervention strategies relies on the knowledge of molecular and cellular mechanisms of corona virus infections, there is urgent need to understand why SARS-CoV-2, in contrast to SARS-CoV, is replicating so efficiently in the upper respiratory tract and which viral and host determinants are decisive on whether COVID-19 patients will develop mild or severe disease. Philip V’kovski et al. (2021)

The unprecedented serious challenge of emergence of HIV virus and AIDS in the precious century has proved that new medicines to tackle the emerging disease can be developed. Azidothymidine (Zidovudine or AZT), which inhibit viral replicase proteins, is used for the treatment of HIV-type1 and 2, and most of the early antiviral drugs, such as acyclovir, were nucleoside and nucleotide analogues, Julia et al. (2005).

3. COVID-19; PROMISING REPLICATING INHIBITORS

SARS-CoV-2 replication is associated with a down regulation of host cell protease inhibitors. The protease inhibitor aprotinin inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. Therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. Aprotinin is a serine protease inhibitor, which has been shown to inhibit transmembrane serine protease 2 (TMPRSS2) and has been suggested as optional treatment for influenza and corona viruses. Aprotinin aerosol may have potential for the early local control of SARS-

Due to the urgent need to control COVID-19 infection pandemic, use of existing antiviral drugs with showed potential inhibiting effects on the replication of coronavirus has been adopted as optional therapeutic tools. Nelfinavir has previously demonstrated antiretroviral activity and used as drug against HIV-type 1. It inhibits the replication of the SARS and SARS-CoV-2-in vitro. It showed potential inhibition against the viral protease such as 3CLpro Norio et al. (2020).

Nucleotide analog drugs can inhibit the viral replication cycle through targeting the viral RNA-dependent RNA polymerase, essential for transcription and replication of RNA genome, such as Favipiravir, which is a guanine analog with activity against many RNA viruses such as SARS-CoV-2 via inhibition the viral RNA-dependent RNA polymerase. It acts as chain terminator. Other drug is Ribavirin and galidesivir, the originally antiviral drugs against the HCV, are able to bind to the RNA-dependent RNA polymerase of SARS-CoV-2 and inhibit the viral RNA synthesis.

Ivermectin is an FDA-approved broad spectrum anti-parasitic agent. Reports suggested that ivermectin’s nuclear transport inhibitory activity may be effective against SARS-CoV-2 Leon et al. (2020)

Lumacaftor and Cepharanthine displayed activity in inhibiting helicase Nsp13 ATPase activity of SARS-CoV-2, essential for viral replication and the most conserved nonstructural protein within the corona virus family, promising that these drugs can be potentially considered for the treatment of COVID-19 Mark et al. (2020). All of these drugs are potential candidates to be evaluated in clinical trials and repurposed for treatment of COVID-19.

4. REMDESIVIR (RDV)

The most promising drug is Remdesivir (RDV), monophosphoramidate prodrug with a molecular mass of 602.6 g/mol and chemical formula C27H35N6O8P. It is known as GS-5734, and metabolized into GS-441524, Frediansyaha et al. (2021). It is an adenosine analog, a primary developed drug by Gilead Sciences of Foster City, California, US. in 2017 to treat the Ebola, and has a potential activity against a wide spectrum of single stranded RNA viruses such as SARS-CoV-2, which acts as an RNA-dependent RNA polymerase inhibitor by binding to the viral RNA-dependent RNA polymerase, and hence, it is an RNA-chain terminator. It is effective as dose of (10mg/kg) for twelve (12) days and it is safety in the human is demonstrated by clinical trials. Ghanbari et al. (2020), Yousefi et al. (2020).

Remdesivir was found to be superior to placebo in shortening the time to recovery in adults who were hospitalized with COVID-19 and had evidence of lowering respiratory tract infection, as suggested by the results of multi-national clinical trial John et al (2020), ClinicalTrials.gov Identifier NCT04292730 (2021), ClinicalTrials.gov Identifier: NCT04292899 (2020)).

Supported by data from multiple clinical trials, Remdesivir (Veklury) is the first authorized medicine by the European Medicine Agency (EMA) for SARS-COV2 treatment on June 25/2020 EMA (2020). It is also the first drug to win full U.S. Food and Drug Administration (FDA) approval for treating COVID-19, in adult and pediatric patients twelve (12) years of age and older and weighing at least forty (40) kilograms, on October 22/2020. Remdesivir should only be administered in healthcare settings capable of providing acute care similar to inpatient hospital care FDA (2020). The adverse reactions known after receiving Remdesivir include...
gastrointestinal disturbances such as nausea and vomiting, hepatotoxicity with elevations of liver enzyme aminotransferase, and infusion related reaction, such as hypotension, and shivering Lam et al. (2020).

5. MOLNUPIRAVIR; THE EXPECTED GAME CHANGER

It is known as (82) Merck bills, a nucleoside analogue, the first oral antiviral treatment for COVID-19 reporting promising clinical trial data. It is developed by Merck- US drug- maker company. It is originally used to treat influenza. It is designed to introduce errors into the genetic code of the virus, when incorporated into viral RNA, shifting its configuration, mimicking the nucleoside cytidine and uridine, causing point mutation, and where deleterious transition mutations accumulate in viral RNA causing lethal mutagenesis, which eventually leading to viral population collapse. Malone and Elizabeth (2021).

Campbell. Trial results suggest molnupiravir needs to be taken early after symptoms develop to have an effect. It can cut hospitalizations and deaths among people with COVID-19 by half (50%). The possibility that molnupiravir could incorporate itself into human DNA, raise safety concerns and need to be monitored Fischer et al. (2021), Sheahan et al. (2020) Cox et al. (2021).

Molnupiravir has been approved in United Kingdom by Medicines and Healthcare Products Regulatory Agency for the treatment of established infections of COVID-19, in November 2021. Mahase (2021). On Friday 19th 2021 EMA; the European Medicines Agency, which is the European Union’s drug regulator, approved emergency use of (Molnupiravir) Merck’s COVID pills for adults who have tested positive for COVID-19 and it prepares to make a decision on full approval by the end of the year.

Molnupiravir along with vaccination, will reduce dramatically the burden on the health systems globally, and speed up the ending of the COVID-19 pandemic.

6. PAXLOVID; ANOTHER REAL GAME-CHANGER

Paxlovid oral bills, developed by Pfizer; US pharmaceutical company contain two components: PF-07321332 and ritonavir. PF-07321332 is protease inhibitor, blocking 3CL protease; 3C-like protease, an endopeptidase, is the main cysteine protease found in coronaviruses. It cleaves the virus polyprotein at eleven conserved sites. 3CL protease inhibitors prevent viral replication by selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors have been used for the treatment of HIV and hepatitis C. Ritonavir prevents cytochrome enzymes from destroying PF-07321332. Ritonavir plays the same defensive role in antiviral drug cocktails for HIV treatment. Paxlovid oral bills are given every twelve (12). hours for five days. It reduces the risk of hospitalization by eighty nine percent (89%). Less than one percent (1%) of patients taking the drug needed to be hospitalized and no death reported in the active group compared to seven percent (7%) hospitalization and ten (10) death, which was about (1.6%) in the placebo group, out of seven hundred and seventy-five (775) adult participant in the clinical trial, as the company announced that on Friday, 5th of November, 2021. It is obviously more effective than Molnupiravir of Merck Company. The side effects of the drugs were mild and reported in about nineteen percent (19%) versus twenty one percent (21%) in the placebo group. Mahase (2021). The Molnupiravir and Paxlovid are expected to be approved and available for COVID-19 patients in most countries before the end of this year 2021.
The challenge faces antiviral therapy is the unpleasant side effects, as well as financial cost. There is urgent need to develop more safe, tolerable and efficacious drugs, with lesser side effects Julia et al. (2005).

7. DISCLAIMER
The information in this review should not be used for diagnosis and treatment of individuals’ problems or in place of a consultation with competent health care professionals.

The author and publisher disclaim all responsibility for any errors or harms occur as the results obtained from use of the information contained in this review.

AUTHOR CONTRIBUTIONS
All authors have contributed significantly to conceptualization of the idea, writing the original draft preparation reviewing and editing. All authors have read and agreed to the published version of the manuscript.

CONFLICTS OF INTEREST
All authors have no conflicts of interest to declare. All authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in the manuscript.

ABBREVIATIONS
DNA; Deyoxyribo nucleic Acid, RNA; Ribonuc leic Acid. EMA; European medicine Agency. EUA; Emergency Use Authorization. FAD; Food and Drugs Administration, CDC; Centers for Disease Control and Prevention. Kb; Kilo base.

REFERENCES


